Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎

Autor:	Palandri, Francesca, Palumbo, Giuseppe A., Iurlo, Alessandra, Polverelli, Nicola, Benevolo, Giulia, Breccia, Massimo, Abruzzese, Elisabetta, Tiribelli, Mario, Bonifacio, Massimiliano, Tieghi, Alessia, Isidori, Alessandro, Martino, Bruno, Sgherza, Nicola, D'Adda, Mariella, Bergamaschi, Micaela, Crugnola, Monica, Cavazzini, Francesco, Bosi, Costanza, Binotto, Gianni, Auteri, Giuseppe, Latagliata, Roberto, Ibatici, Adalberto, Scaffidi, Luigi, Penna, Domenico, Cattaneo, Daniele, Soci, Francesco, Trawinska, Malgorzata, Russo, Domenico, Cuneo, Antonio, Semenzato, Giampietro, Di Raimondo, Francesco, Aversa, Franco, Lemoli, Roberto M., Heidel, Florian, Reggiani, Maria L.B., Bartoletti, Daniela, Cavo, Michele, Catani, Lucia, Vianelli, Nicola
Zdroj:	In Seminars in Hematology October 2018 55(4):248-255
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu